Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced that Somatuline^® Autogel^® (lanreotide), telotristat ethyl and the investigational compound ¹⁷⁷Lu-OPS201 are the subject of 23 presentations at the European Neuroendocrine Tumor Society (ENETS) 2017 conference.

“We are very excited to participate in this meeting and to share data regarding lanreotide, telotristat ethyl and ¹⁷⁷Lu-OPS201,” said Dr. Sotirios Stergiopoulos, SVP Head of Global Medical Affairs, Ipsen. “In addition, Ipsen supported several projects to understand the biology, epidemiology, treatment patterns and unmet needs of patients living with Neuroendocrine Tumors (NETs). All of this demonstrates IPSEN’s  commitment to improving the life of patients living with NETs.”

Lanreotide (Somatuline^® Autogel^®) is featured in 17 presentations:

ABSTRACTS SELECTED FOR ORAL PRESENTATIONS

[A10]   Krug S et al. Interactions between SSTR Modulation via Lanreotide and Molecular Targeted Therapies in Sequential and Combination Approaches in Vitro. Session: ENETS/NANETS Young Investigator Symposium

[K12]   Martínez-López A et al. Efficacy of Lanreotide (LAN), both Alone and in Combination with Targeted Therapies in a Preclinical Model of Pancreatic Neuroendocrine Tumors (pNETs). Session: 4A – Basic Science Abstracts

ABSTRACTS SELECTED FOR POSTER SESSION

[K17]   Phan AT et al. Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

[K18]   Phan AT et al. Long-Term Efficacy and Safety with Lanreotide Autogel/Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies

[K5]     Duchateau L et al. An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)

 [C5]    Meyer T et al. CALM-NET, A Multicentre, Exploratory Study to Assess the Clinical Value of Circulating Tumour Cells (CTCs) Enumeration in Patients (Pts) with Functioning Midgut NETs Receiving Lanreotide Autogel (LAN)

[K1]     Albertelli M et al. Safety and Efficacy of High Doses Lanreotide Treatment in Patients with Progressive Neuroendocrine Tumors: Results from a Prospective Phase II Trial. Note: This is an investigator-sponsored trial.

[K15]   Pavel M et al.             Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Patients with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study

[J8]      Lepage C et al. REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors. Note: This is an investigator-sponsored trial.

[K2]     Almquist M et al. STREET – Somatostatin Treatment Experience Trial

[A12]   Lelek S et al. Antiproliferative Effects of Lanreotide in Neuroendocrine Tumors. Note: This is an investigator-sponsored trial.

[K20]   Reidy-Lagunes D et al. Lanreotide Autogel/Depot (LAN) in Lung Neuroendocrine Tumours (NETs): The Randomized, Double-Blind, Placebo (PBO)-Controlled, International Phase 3 SPINET Study

[K7]     Ferolla P et al. Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT

[K9]     Geilvoet W et al. Patient Satisfaction Regarding Home Injection Service for Somatostatin Analogues: A Survey among Patients with a Neuroendocrine Tumour. Note: This is an investigator-sponsored trial.

[N15]   Prasad V et al. Lanreotide Autogel/Depot (LAN) in Combination with Peptide Receptor Radionuclide Therapy (PRRT) in Progressive Digestive and Lung Neuroendocrine Tumours (NETs): Design of the PRELUDE Study

[Q36]   van Fraeyenhove F et al. Tumor Growth Rate to Assess Tumor Activity in Patients with Lung Neuroendocrine Tumors on Lanreotide Autogel: A Case-Series Analysis. Note: This is an investigator-sponsored trial.

[K19]   Prinzi N et al. Safety of Lanreotide 120 mg ATG (LAN) in Combination with Metformin (MET) in Patients (pts) with Progressive Advanced Well-Differentiated (WD) Gastro-Intestinal (GI) or Lung Carcinoids. A Pilot, One-Arm, Open-Label, Prospective Study: The MetNET-2 Trial. Note: This is an investigator-sponsored trial.

Telotristat ethyl is featured in 5 presentations:

ABSTRACTS SELECTED FOR POSTER SESSION

 [K16]  Pavel M et al. Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial

[L2]      Anthony L et al. Impact of Concomitant Medication on Efficacy of Telotristat Ethyl – A Post Hoc Subgroup Analysis of the Phase 3 TELESTAR Study in Carcinoid Syndrome

[L7]      Lapuerta P et al. Integrated Safety Analysis of Telotristat Ethyl in Patients with Carcinoid Heart Disease

[M3]    Cella D et al. Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial

[M8]    Pavel M et al. Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study

¹⁷⁷Lu-OPS201 is featured in one presentation:

ABSTRACT SELECTED FOR POSTER SESSION

[N12]   Nicolas G et al. Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201